Corporate Presentation

Obesity Petrelintide A single subcutaneous dose of petrelintide 2.4 mg resulted in average weight loss of 4.2% at Day 7 Change in body weight in Phase 1a SAD trial of petrelintide ZEAL& ZEALAND PHARMA Change in body weight (%) 0 + Placebo +0.6% (n=6) -8 07 Petrelintide 0.7 mg (n=6) -2.6% 24 21 42 0 7 Petrelintide 1.4 mg (n=6) -3.6% Petrelintide 2.4 mg (n=6) -4.2% 24 21 42 0 7 Days from dose 21 42 0 7 Source: Figure adapted from Olsen et al. Poster 92-LB. Presented at ADA 83rd Scientific Sessions, June 23-26, 2023, San Diego, CA. SAD=single ascending-dose. 21 24 42 15

View entire presentation